Esperion Therapeutics, Inc. (ESPR) SEC Filing 10-Q Quarterly report for the period ending Saturday, June 30, 2018

Esperion Therapeutics, Inc.

CIK: 1434868 Ticker: ESPR

Exhibit 99.1




Investor Contact:


Alex Schwartz








Media Contact:


Elliot Fox


W2O Group




Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2018 Financial Results


Ann Arbor, Mich., — (Globe Newswire — August 2, 2018) — Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today provided bempedoic acid franchise development program updates and financial results for the second quarter ended June 30, 2018.


“The Lipid Management Team has made tremendous progress during the first half of 2018, with positive top-line results reported from three pivotal Phase 3 studies and one Phase 2 study.  Full results of completed Phase 3 studies are being prepared for presentation and publication, with full Study 4 results already presented and published last month.  Additionally, at our recent Investor Day, key opinion leaders expressed their agreement that bempedoic acid is safe and well-tolerated, and has demonstrated clinically meaningful LDL-C lowering in completed Phase 2 and 3 studies,” said Tim M. Mayleben, president and chief executive officer of Esperion.  “We remain on-track to report top-line results for the final two pivotal Phase 3 studies at the end of August and September, as well as submit NDAs no later than the first quarter of 2019.  We are on the cusp of delivering two once-daily, oral bempedoic acid-based LDL-cholesterol lowering therapies to the millions of patients who are inadequately treated with, or unable to gain access to, current LDL-C lowering therapies.”


Second Quarter Development Program Highlights


May 2018:


·                  Announced positive top-line results from the global, pivotal Phase 3 long-term study (Study 1 or 1002-040) of bempedoic acid 180 mg evaluating the safety and tolerability of bempedoic acid versus placebo in very high-risk patients with atherosclerotic cardiovascular disease (ASCVD) who are inadequately controlled with current lipid-modifying therapies, including maximally tolerated statin therapy.  Bempedoic acid was


The following information was filed by Esperion Therapeutics, Inc. (ESPR) on Thursday, August 2, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Esperion Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Esperion Therapeutics, Inc..


Assess how Esperion Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Esperion Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools


Learn More
Bullish Bearish Neutral
Filter Sentiment:
Filter Category:
M & A
Filter Subcategory:
Shares / Equity
Inside Esperion Therapeutics, Inc.'s 10-Q Quarterly Report:

Material Contracts, Statements, Certifications & more

Esperion Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ESPR
CIK: 1434868
Form Type: 10-Q Quarterly Report
Accession Number: 0001104659-18-049208
Submitted to the SEC: Thu Aug 02 2018 4:31:47 PM EST
Accepted by the SEC: Thu Aug 02 2018
Period: Saturday, June 30, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: